Table 7 Univariate analysis of the expression of metabolism-related proteins in breast cancers and disease-free survival or overall survival by logrank test ^a

Glut-1 in tumor

0.010

0.023

 Negative

504/37/37

128 (125 to 131)

131 (128 to 134)

 Positive

236/32/30

119 (112 to 126)

123 (118 to 128)

Glut-1 in stroma

n/a

n/a

 Negative

724/69/67

n/a

n/a

 Positive

16/0/0

n/a

n/a

CAIX in tumor

0.740

0.222

 Negative

520/49/45

126 (122 to 130)

130 (127 to 132)

 Positive

220/20/22

108 (102 to 113)

123 (117 to 130)

CAIX in stroma

0.927

0.496

 Negative

627/59/56

125 (122 to 129)

129 (126 to 132)

 Positive

113/10/11

103 (98 to 108)

116 (109 to 123)

ATP synthase in tumor

0.506

0.936

 Negative

30/4/3

102 (90 to 114)

129 (117 to 141)

 Positive

710/65/64

125 (122 to 129)

128 (126 to 131)

ATP synthase in stroma

0.783

0.398

 Negative

570/53/50

125 (121 to 129)

129 (126 to 132)

 Positive

170/16/17

118 (112 to 124)

122 (115 to 128)

Glutaminase in tumor

0.323

0.164

 Negative

219/24/25

123 (117 to 128)

126 (120 to 131)

 Positive

521/45/42

126 (122 to 130)

130 (127 to 133)

Glutaminase in stroma

0.554

0.596

 Negative

495/49/48

123 (119 to 128)

128 (125 to 131)

 Positive

245/20/19

127 (121 to 132)

128 (124 to 133)

BNIP3 in tumor

0.004

0.426

 Negative

504/59/50

123 (119 to 127)

128 (124 to 131)

 Positive

236/10/17

123 (119 to 127)

131 (126 to 135)

BNIP3 in stroma

0.191

0.973

 Negative

700/68/64

125 (121 to 128)

128 (126 to 131)

 Positive

40/1/3

116 (111 to 121)

121 (112 to 129)

MCT4 in tumor

0.550

0.451

 Negative

540/49/47

125 (121 to 129)

129 (126 to 132)

 Positive

200/20/20

116 (111 to 121)

126 (120 to 131)

MCT4 in stroma

0.673

0.262

 Negative

418/42/44

123 (118 to 127)

127 (123 to 131)

 Positive

322/27/23

128 (124 to 132)

130 (126 to 133)

Cytoplasmic beclin-1

0.169

0.566

 Negative

406/46/38

124 (119 to 128)

129 (126 to 132)

 Positive

334/23/29

121 (118 to 124)

126 (123 to 130)

Nuclear beclin-1

0.157

0.031

 Negative

666/66/66

125 (121 to 128)

128 (125 to 131)

 Positive

74/3/1

111 (106 to 115)

136 (132 to 139)

LC3A in tumor

0.085

0.299

 Negative

669/59/59

126 (122 to 129)

129 (126 to 132)

 Positive

71/10/8

113 (103 to 122)

124 (115 to 133)

LC3A in stroma

0.801

0.541

 Negative

687/65/64

125 (122 to 129)

128 (126 to 131)

 Positive

53/4/3

65 (62 to 68)

66 (64 to 68)

LC3B in tumor

0.990

0.271

 Negative

475/45/40

125 (121 to 130)

130 (127 to 133)

 Positive

265/24/27

118 (113 to 123)

125 (120 to 130)

LC3B in stroma

0.481

0.565

 Negative

688/66/64

125 (122 to 129)

128 (126 to 131)

 Positive

52/3/3

63 (60 to 66)

64 (62 to 66)

Cytoplasmic p62 in tumor

0.958

0.528

 Negative

274/26/23

121 (112 to 129)

129 (125 to 133)

 Positive

466/43/44

126 (122 to 130)

128 (125 to 131)

Nuclear p62 in tumor

0.210

0.646

 Negative

532/55/51

125 (122 to 129)

128 (125 to 131)

 Positive

208/14/16

117 (110 to 124)

128 (122 to 133)

Nuclear p62 in stroma

0.720

0.387

 Negative

512/48/45

126 (122 to 130)

129 (126 to 132)

 Positive

228/21/22

104 (99 to 109)

124 (118 to 130)

Tumor phenotype

<0.001

<0.001

 Luminal A

298/15/14

130 (126 to 133)

134 (131 to 137)

 Luminal B

166/12/11

129 (124 to 134)

130 (124 to 135)

 HER2

69/11/12

111 (100 to 121)

119 (108 to 130)

 TNBC

207/31/30

116 (109 to 124)

120 (114 to 126)

Metabolic status

0.037

0.045

 Warburg type

298/38/36

119 (112 to 126)

124 (119 to 128)

 Reverse Warburg type

54/6/5

90 (83 to 96)

113 (106 to 121)

 Mixed type

62/4/6

105 (100 to 111)

112 (99 to 126)

 Null type

326/21/20

129 (126 to 133)

132 (129 to 136)